{"nctId":"NCT00085735","briefTitle":"Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma","startDateStruct":{"date":"2004-04-30","type":"ACTUAL"},"conditions":["Medulloblastoma"],"count":549,"armGroups":[{"label":"Arm I (3-7 years of age, LDCSI, IFRT)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Radiation: Involved-Field Radiation Therapy","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Drug: Vincristine Sulfate"]},{"label":"Arm II (3-7 years of age, LDCSI, PFRT)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Radiation: Radiation Therapy","Drug: Vincristine Sulfate"]},{"label":"Arm III (3-7 years of age, SDCSI, IFRT)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Radiation: Involved-Field Radiation Therapy","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Drug: Vincristine Sulfate"]},{"label":"Arm IV (3-7 years of age, SDCSI, PFRT)","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Radiation: Radiation Therapy","Drug: Vincristine Sulfate"]},{"label":"Arm V (8-21 years of age, SDCSI, IFRT)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Radiation: Involved-Field Radiation Therapy","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Drug: Vincristine Sulfate"]},{"label":"Arm VI (8-21 years of age, SDCSI, PFRT)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin","Radiation: Craniospinal Irradiation","Drug: Cyclophosphamide","Other: Laboratory Biomarker Analysis","Drug: Lomustine","Other: Quality-of-Life Assessment","Radiation: Radiation Therapy","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Craniospinal Irradiation","otherNames":[]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Asta B 518","B 518","B-518","B518","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR 138719","WR- 138719","WR-138719","WR138719"]},{"name":"Involved-Field Radiation Therapy","otherNames":["IFRT","Involved field radiotherapy"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Lomustine","otherNames":["1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea","1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-","Belustin","Belustine","CCNU","Cecenu","CeeNU","Chloroethylcyclohexylnitrosourea","Citostal","Gleostine","Lomeblastin","Lomustinum","Lucostin","Lucostine","N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea","Prava","RB-1509","WR-139017"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed medulloblastoma located in the posterior fossa\n\n  * Standard-risk disease\n* Minimal volume, non-disseminated disease, defined by the following:\n\n  * Residual tumor ≤ 1.5 cm\\^2 confirmed by MRI with contrast imaging within 21 days after surgery\n  * No metastatic disease in the head, spine, or cerebrospinal fluid (CSF) confirmed by both of the following:\n\n    * Enhanced MRI of the spine within 5 days before surgery OR within 28 days after surgery\n    * Negative cytological examination of CSF after surgery, but before study enrollment\n* Brain stem involvement allowed\n* Performance status - Karnofsky 50-100% (\\> 16 years of age)\n* Performance status - Lansky 30-100% (≤ 16 years of age)\n* Absolute neutrophil count \\> 1,500/uL\n* Platelet count \\> 100,000/uL (transfusion independent)\n* Hemoglobin \\> 10 g/dL (transfusions allowed)\n* Bilirubin \\< 1.5 times upper limit of normal (ULN) for age\n* AST or ALT \\< 1.5 times ULN for age\n* Creatinine clearance OR radioisotope glomerular filtration rate \\>= 70 mL/min/1.73m\\^2 or a serum creatinine based on age/gender as follows:\n\nAge Maximum Serum Creatine (mg/dL)\n\n* 1month to \\< 6 months male: 0.4 female: 0.4\n* 6 months to \\<1 year male: 0.5 female: 0.5\n* 1 year to \\< 2 years male: 0.6 female: 0.6\n* 2 to \\< 6 years male: 0.8 female: 0.8\n* 6 to \\< 10 years male: 1 female: 1\n* 10 to \\< 13 years male: 1.2 female: 1.2\n* 13 to \\< 16 years male: 1.5 female: 1.4\n* \\>= 16 years male: 1.7 female: 1.4\n\n  * Not pregnant or nursing\n  * Negative pregnancy test\n  * Fertile patients must use effective contraception\n  * No prior chemotherapy\n  * Prior corticosteroids allowed\n  * No prior radiotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS)","description":"EFS was defined as the time interval from date of study entry to date of disease progression, disease recurrence, second malignant neoplasm or death from any cause, whichever occurs first, or to the date of last follow-up for patients without events. EFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% confidence intervals (CI's).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"85.8","spread":null},{"groupId":"OG003","value":"85.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy \\[IFRT\\]) are combined and compared to arms II, IV and VI (posterior fossa irradiation \\[PFRT\\]).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"90.3","spread":null},{"groupId":"OG003","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"90.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Posterior Fossa (LPF) Failure Rate","description":"LPF failure was defined as tumor recurrence/progression within the tumor bed. The cumulative incidence (CI) of LPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF) and with other events prior to LPF failure (e.g., death, second malignancy) were considered as having competing events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-local Posterior Fossa (NLPF) Failure Rate","description":"NLPF failure was defined as tumor recurrence/progression outside the radiation therapy clinical target volume boost (CTV-boost) but within the posterior fossa CTV (CTV-PF). The cumulative incidence (CI) of NLPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF, LPF) and with other events prior to NLPF failure (e.g., death, second malignancy) were considered as having competing events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Non-posterior Fossa (NPF) Failure Rate","description":"NPF failure was defined as tumor recurrence within the neuroaxis but outside the radiation therapy clinical target volume (CTV). The cumulative incidence (CI) of NPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., LPF failure) and with other events prior to NPF failure (e.g., death, second malignancy) were considered as having competing events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-treatment Endocrine Function by CSI Group","description":"Post-treatment endocrine function was measured by laboratory assessment of the thyroid stimulating hormone (TSH). The mean TSH will be reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"5.6"},{"groupId":"OG001","value":"6.1","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4","description":"Proportions of patients with grade 3+ hearing loss after the completion of therapy will be calculated and reported separately for low dose craniospinal irradiation (LDCSI) versus (vs.) standard dose craniospinal irradiation (SDCSI) patients. Eligible and evaluable patients 3-7 years of age will be used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).","description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 4-15 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":"14.4"},{"groupId":"OG001","value":"96.2","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)","description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 27-48 months post diagnosis, only the assessments before progression date were reported. The range of FSIQ is 50 - 150. A higher FSIQ is better.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":"12.5"},{"groupId":"OG001","value":"90.5","spread":"13.3"}]}]}]},{"type":"SECONDARY","title":"Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)","description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 49-72 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":"15.4"},{"groupId":"OG001","value":"86.4","spread":"13.5"}]}]}]},{"type":"SECONDARY","title":"Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4","description":"Proportions of patients with grade 3+ hearing impairment as assessed by CTCAE v4 at 1-year post treatment were calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group","description":"Endocrine dysfunction was assessed by growth hormone stimulation (GHS) tests. We report the percentage of patients with abnormal growth hormone stimulation tests.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays","description":"OS was defined as the time interval from date of study entry to date of death from any cause or to date of last contact for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":null},{"groupId":"OG001","value":"97.3","spread":null},{"groupId":"OG002","value":"92.0","spread":null},{"groupId":"OG003","value":"98.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays","description":"PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"90.6","spread":null},{"groupId":"OG002","value":"90.4","spread":null},{"groupId":"OG003","value":"98.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)","description":"Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":"11.1"},{"groupId":"OG001","value":"51.3","spread":"9.6"}]}]}]},{"type":"SECONDARY","title":"Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)","description":"Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":"10.6"},{"groupId":"OG001","value":"55.0","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)","description":"Metacognition index (MI) was measured by BRIEF test. Assessments within the time window, from eligible and evaluable patients are reported. If the patient had disease progression, only the assessments before progression date were reported. The MI is a standard T- score, and it ranges from 0 to 100. The higher score reported suggests a higher level of dysfunction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":"10.7"},{"groupId":"OG001","value":"58.6","spread":"11.3"}]}]}]},{"type":"SECONDARY","title":"Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)","description":"Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 4 - 15 months post diagnosis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)","description":"Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 27 - 48 months post diagnosis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)","description":"Compliance rates are calculated to monitor the compliance with long-term quality of life and functional status data submission. A patient will be compliant if the patient has metacognition index score. Compliance rates will be assessed at each of the 3 neurocognitive/quality of life assessment time windows. All eligible and evaluable patients enrolled will be used. Patients removed from treatment prior to the time of neuropsychological assessment (for reasons such as disease progression, death, withdrawal of consent, etc.) will not be included in the denominator to assess the compliance rate. The time window is 49 - 72 months post diagnosis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":63},"commonTop":["Neutrophil count decreased","Platelet count decreased","Alanine aminotransferase increased","Aspartate aminotransferase increased","Peripheral motor neuropathy"]}}}